louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04650113: Clinical and Radiographic Assessment of Partial and Complete Pulpotomy in Primary Molars Using MTA
Official title: Clinical and Radiographic Assessment of Partial and Complete Pulpotomy in Primary Molars Using MTA : A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Pulp Disease, Dental
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2020-12-02
Enrollment: 1
Sex: ALL
Minimum age (years): 4
Maximum age (years): 7
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: that's comparison between partial and complete pulpotomy techniques in primary teeth


Eligibility criteria: Inclusion Criteria:

1. - Medically free children who will be able and cooperative in all steps of the study.
2. - Asymptomatic primary molars with a deep carious lesion.
3. - Vital pulp due to dental caries with no clinical sign of pulpal degeneration (spontaneous pain, fistula, mobility) prior to treatment.

3 - Preliminary radiographs indicating absence of pathologic internal or external root resorption, or any evidence of inter-radicular bone destruction.

4 - Absence of pre-operative pain or they will only have a short-term pain. 5 - No tenderness to percussion. 6-Age ranging 4-6 years.

Exclusion Criteria:

1- Excessive bleeding during pulp amputation. 2 - Non vital teeth. 3 -History of spontaneous or prolonged pain. 4 - Swelling, tenderness, to percussion or palpation, or pathologic mobility. 5 - pre-operative radiographic pathology such as resorption (internal, external); periradicular or furcation radiolucency, or a widened periodontal ligament space.

6 - Parent or guardians who refuse participating in the study

Primary outcomes:
measure: postoperative pain
timeFrame: 1 week
measure: postoperative pain
timeFrame: 1 month
measure: postoperative pain
timeFrame: 3 months
measure: postoperative pain
timeFrame: 6 months
measure: swelling
timeFrame: 1 week
measure: swelling
timeFrame: 1 month
measure: swelling
timeFrame: 3 months
measure: swelling
timeFrame: 6 months
measure: mobility
timeFrame: 1 week
measure: mobility
timeFrame: 1 month
measure: mobility
timeFrame: 3 months
measure: mobility
timeFrame: 6 months
Secondary outcomes:
measure: root resorption
timeFrame: 1 week
measure: root resorption
timeFrame: 1 month
measure: root resorption
timeFrame: 3 months
measure: root resorption
timeFrame: 6 months
measure: Bone resorption
timeFrame: 1 week
measure: Bone resorption
timeFrame: 1 month
measure: Bone resorption
timeFrame: 3 months
measure: Bone resorption
timeFrame: 6 months
Other outcomes:
Locations:
city: Al Manyal
country: Egypt
facility: Faculty of dentistry cairo university
state: Cairo
Study officials:
affiliation: Associate Professor of Pediatric Dentistry and Dental Public Health, Faculty of Dentistry cairo university
name: adel El-bardissy, prof
role: STUDY_DIRECTOR
affiliation: Lecturer of Pediatric Dentistry and Dental Public Health, Faculty of Dentistry cairo university
name: rasha ragab, phd
role: STUDY_DIRECTOR
References:
Clinical trial NCT02988713: Study to Characterize Effects of Programming in SCS Patients Undergoing a Temporary Trial
Official title: Study to Characterize the Effects of Programming Spinal Cord Stimulation (SCS) in Patients Undergoing a Boston Scientific (BSC) SCS Temporary Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Pain
Keywords: stimulation
chronic pain
back pain
leg pain
Lead sponsor: Boston Scientific Corporation
Sponsor class: INDUSTRY
First posted: 2016-12-09
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: This is a prospective, multi-center, non-randomized, exploratory, single-arm study characterize the effects of programming spinal cord stimulation (SCS) in patients undergoing a Boston Scientific (BSC) spinal cord stimulation (SCS) temporary trial


Eligibility criteria: Key Inclusion Criteria:

* Study candidate is undergoing a spinal cord stimulation (SCS) trial of BSC neurostimulation system, per local directions for use (DFU).
* Subject signed a valid, Institutional Review Board (IRB)-approved informed consent form.
* Subject is 18 years of age or older when written informed consent is obtained.

Key Exclusion Criteria:

* Subject meets any contraindication in BSC neurostimulation system local directions for use (DFU).

Primary outcomes:
measure: Patient Comfort
timeFrame: An estimated average of 7 days post temporary trial procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Ventura
country: United States
facility: Pacific Pain Management, Inc.
state: California
city: Greenville
country: United States
facility: PCPMG Clinical Research Unit, LLC
state: South Carolina
Study officials:
affiliation: Boston Scientific Corporation
name: Roshini Jain, M.S.
role: STUDY_DIRECTOR
References:
Clinical trial NCT00405613: Aspirin Use and Postoperative Bleeding From Dental Extractions in a Healthy Population
Official title: Aspirin Use and Postoperative Bleeding From Dental Extractions in a Healthy Population
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Bleeding Complication
Keywords: Aspirin
Bleeding
Clinical Trial
Dental Extraction
Lead sponsor: Wake Forest University Health Sciences
Sponsor class: OTHER
First posted: 2006-11-30
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if aspirin is associated with bleeding complications following a single tooth extraction

Detailed description: Aspirin is a common chronically administered preventive treatment for cardiovascular disease, but is often discontinued prior to invasive dental procedures because of concern of bleeding complications. As the goal of aspirin is often to prevent MI and stroke, the risk of these CVD outcomes with discontinuation of aspirin must be weighed against the perceived adverse event of bleeding during or following an invasive dental procedure with continuation of aspirin. The current study is a randomized controlled trial evaluating bleeding complications of aspirin vs. placebo in healthy patients schedule for a single tooth extraction.

Eligibility criteria: Inclusion Criteria:

* Healthy
* Require a simple tooth extraction

Exclusion Criteria:

* Use of previous aspirin or NSAID

Primary outcomes:
measure: Oral bleeding time
Secondary outcomes:
measure: Report of bleeding at phone follow-up at 3-7 (first follow-up) and 40-55 hours (second follow-up)
Other outcomes:
Locations:
city: Charlotte
country: United States
facility: Carolinas Medical Center
state: North Carolina
Study officials:
affiliation: Carolinas Medical Center
name: Michael T Brennan, DDS,MHS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01125813: Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A
Official title: Clinical Study to Investigate the Efficacy, Safety, and Immunogenicity of Human-cl rhFVIII in Previously Treated Patients With Severe Hemophilia A
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Severe Hemophilia A
Lead sponsor: Octapharma
Sponsor class: INDUSTRY
First posted: 2010-05-18
Enrollment: 32
Sex: MALE
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: This study will determine the efficacy of human-cl rhFVIII in previously treated patients with severe hemophilia A during prophylactic treatment, treatment of bleeding episodes and in surgical prophylaxis.


Eligibility criteria: Inclusion Criteria:

* Severe hemophilia A ((FVIII:C \<= 1%)
* Male subjects \>= 12 years of age
* Previously treated with FVIII concentrate, at least 50 EDs
* Immunocompetent (CD4+ count \> 200/ul)
* Negative for anti- HIV; if positive, viral load \< 200 particles/u; or \<400,000 copies/mL

Exclusion Criteria:

* Other coagulation disorder than hemophilia A
* Present of past FVIII inhibitor activity (.= 0.6 BU)
* Severe liver and kidney disease
* Receiving of scheduled to receive immuno-modulating drugs

Primary outcomes:
measure: Efficacy Assessment After a Total of at Least 50 EDs Per Subject at the End of the Study at 6 Months
timeFrame: At least 50 Exposure Days and at least 6 months
measure: Efficacy of Treating Bleeding Episodes
timeFrame: After each bleeding episode, up to 6 month
Secondary outcomes:
Other outcomes:
Locations:
city: Wien
country: Austria
facility: Medizinische Universitaet Wien
city: Sofia
country: Bulgaria
facility: Haematological Hospital Joan Pavel
city: Hannover
country: Germany
facility: Werlhof Institut fuer Haemostaseologie GmbH
state: Niedersachsen
city: Bonn
country: Germany
facility: Universitaetsklinikum
city: Hamburg
country: Germany
facility: Universitaetsklinikum Hamburg-Eppendorf
city: Heidelberg
country: Germany
facility: SRH Kurpfalzkrankenhaus Heidelberg
city: Basingstoke
country: United Kingdom
facility: Basingstoke & North Hampshire NHS Foundation Trust
city: Cardiff
country: United Kingdom
facility: University Hospital of Wales
city: London
country: United Kingdom
facility: Royal Free Hospital
city: Manchester
country: United Kingdom
facility: Manchester Royal Infirmary
city: Sheffield
country: United Kingdom
facility: Royal Hallamshire Hospital
Study officials:
affiliation: Universitaetsklinikum Bonn
name: Johannes Oldenburg, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04680013: Genetic Studies in Familial Dementia
Official title: Genetic Studies in Familial Dementia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Dementia of Alzheimer Type
Alzheimer Disease, Late Onset
Alzheimer Disease, Early Onset
Mild Cognitive Impairment
Dementia
Keywords: Memory loss
Lead sponsor: University of Miami
Sponsor class: OTHER
Collaborators: name: Case Western Reserve University
name: Columbia University
name: Wake Forest University
name: National Institute on Aging (NIA)
First posted: 2020-12-22
Enrollment: 4884
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population consists of older individuals affected by dementia, mild cognitive impairment, cognitive controls, or their family members. Ascertainment is across both males and females, and all race-ethnic groups.

Brief summary: The purpose of this study is to identify genetic factors that contribute to or cause dementia (loss of memory) and related disorders across all ages and ethnic groups. This includes a number of neurological diseases such as early and late-onset Alzheimer disease, mild cognitive impairment, and other dementias.


Eligibility criteria: Inclusion Criteria:

1. 18 years and older
2. Patients diagnosed with dementia, their family members and unrelated healthy controls without dementia.

Exclusion Criteria:

1. Individuals with competing diagnosis such as: Amyotrophic lateral sclerosis, Frontotemporal lobar degeneration, Multiple system atrophy, Corticobasal degeneration, Progressive Supranuclear Palsy, Huntington's disease, traumatic brain injury, drug or alcohol abuse, or schizophrenia, etc. (unless family members of a dementia affected individual).

Primary outcomes:
measure: Correlation between genetic factors and Alzheimer disease, dementia, and related phenotypes.
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Miami
country: United States
facility: University of Miami
state: Florida
Study officials:
affiliation: University of Miami
name: Margaret Pericak-Vance, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02308813: Predictability of the Ability to Perform an Emergency Stop With Disorders of the Hip
Official title: Predictability of Braking Performance in Patients With Degenerative Disease of the Hip Joint or With Total Hip Arthroplasty
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Osteoarthritis
Total Hip Arthroplasty
Lead sponsor: University Hospital Tuebingen
Sponsor class: OTHER
First posted: 2014-12-04
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Several studies exist on patient performance in drive simulators especially around and after surgery. Recommendations concerning the ability to drive preoperatively are based on these studies, which generated their data using drive simulators. However, in all the datasets driving performance remains highly individual. Since a drive simulator is not readily available in normal general practitioner surgeries it would be helpful to have convenient clinical tests to evaluate a patients individual ability to perform an emergency stop. This study aims at evaluating different possibilities how such performance might be predicted. Patients with hip osteoarthritis and patients who have received total hip arthroplasty are tested clinically and their results are compared with the gold standard experiment - a drive simulator.


Eligibility criteria: Inclusion Criteria:

* 18-85 y
* valid driving license
* male and female
* Hip Osteoarthritis, Total hip arthroplasty
* capability to walk with or without a walking stick

Exclusion Criteria:

* myocardial infarction/Apoplexia \< 6 months
* Total hip arthroplasty \<5 weeks
* New York Heart Association 3/4
* lacking drivers' license
* peripheric sensomotor deficit \<3/5 British Medical Research Council
* new fracture of the lower extremity or spine
* systemic or metastasised Cancer
* drug intake with centrally acting substances known to affect reaction time (Opioids, e.g. Tramadol, oxycodone, morphine, Til

Primary outcomes:
measure: Correlation of an index of manual reaction time combined with functional hip tests and braking performance
timeFrame: Osteoarthritis group: cross sectional at consultation, Total hip arthroplasty group: cross-sectional - from 5 weeks postoperatively until 400 months postoperatively, at consultation
Secondary outcomes:
Other outcomes:
Locations:
city: Tuebingen
country: Germany
facility: University Hospital Tuebingen, Department of Orthopaedics
Study officials:
affiliation: University Hospital Tuebingen
name: Ulf K Hofmann, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hau R, Csongvay S, Bartlett J. Driving reaction time after right knee arthroscopy. Knee Surg Sports Traumatol Arthrosc. 2000;8(2):89-92. doi: 10.1007/s001670050192.
Clinical trial NCT00943813: Assessment of Comskil Training Through Videorecording and Patient Surveys
Official title: Assessment of Comskil Training Through Videorecording and Patient Surveys
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Comskil Training
Keywords: communication
survey
video
09-043
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2009-07-22
Enrollment: 55
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: MSKCC new visits in clinic.

Brief summary: At Memorial Sloan-Kettering Cancer Center the investigators want to provide the best care to their patients. One way to do this is to evaluate the ways that doctors communicate with patients. To this end, the Department of Psychiatry and Behavioral Sciences runs a Communication Skills Training and Research Laboratory. One goal of this laboratory is to evaluate doctor-patient communication and provide training in how to improve the quality of this communication.

Invitation to participate in this pilot project does not mean that a problem with communication has been identified in your doctor's practice. Rather, it is because your doctor and the fellow working with your doctor have agreed to cooperate with us as the investigators develop strategies to train physicians, nurses and other clinical personnel to communicate with cancer patients in as effective and sensitive a manner as possible.


Eligibility criteria: Inclusion Criteria:

* Over 18 years of age;
* Able to understand and provide signature on permission form (Appendix II)
* Able to speak and read English

Exclusion Criteria:

* Evidence of cognitive impairment severe enough to preclude giving permission to the study staff, or completing the survey instrument of the study.

Primary outcomes:
measure: To obtain data from patients about their satisfaction with the fellows' communication and their perception of the fellows' use of communication skills.
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Philip Bialer, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06282913: The Effect of Mindfulness Meditation
Official title: The Effect of Mindfulness Meditation Practice on Compassion Fatigue, Burnout, and Psychological Well-Being of Health Professionals Working in Oncology Units: Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Burnout
Compassion Fatigue
Psychological Well-Being
Keywords: Mindfulness meditation
compassion fatigue
burnout
psychological well-being
oncology units
health professionals
Lead sponsor: Gulhane Training and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2024-02-28
Enrollment: 64
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Cancer is a disease that causes the most deaths worldwide and is challenging for patients and caregivers both physically and psychosocially. Physicians and nurses working in oncology clinics perform a demanding profession providing compassionate care and treatment to patients struggling with life-threatening diseases. The emotional cost of caring for patients diagnosed with cancer can lead to compassion fatigue, burnout, and decreased psychological well-being among healthcare professionals. For this reason, this research is planned as a randomized controlled study to examine the effect of Mindfulness meditation practice on compassion fatigue, burnout, and psychological well-being in physicians and nurses working in oncology units.


Eligibility criteria: Inclusion Criteria:

* Actively working in oncology clinics
* At least 1 year of working experience in an oncology clinic
* Not having a physical/mental/psychological disorder that would prevent participation in the research.
* Oncology nurses with a high school, undergraduate, associate or graduate degree in nursing
* Physicians and nurses who volunteer to participate in the research will be included in the research sample.

Exclusion Criteria:

* Physicians and nurses who have been diagnosed with a psychological disease in the last two years and are continuing their medical treatment • Physicians and nurses who did not agree to participate in the research

Primary outcomes:
measure: compassion fatigue
timeFrame: up to 8 weeks
measure: burnout
timeFrame: up to 8 weeks
measure: psychological well-being
timeFrame: up to 8 weeks
Secondary outcomes:
measure: compassion fatigue
timeFrame: up to 12 weeks
measure: burnout
timeFrame: up to 12 weeks
measure: psychological well-being
timeFrame: up to 12 weeks
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Dr. Abdurrahman Yurtaslan Oncology Hospital
Study officials:
References:
Clinical trial NCT00977613: Adherence to a Recommended Exercise Regimen in Colorectal Cancer Patients
Official title: Prospective Evaluation of Adherence to Recommended Activity Regimen in Patients Following Treatment of Stages II and III Colorectal Cancer.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Colorectal Cancer (CRC)
Keywords: Treated Stage 2 and Stage 3 colorectal cancer
Lead sponsor: Beth Israel Medical Center
Sponsor class: OTHER
First posted: 2009-09-16
Enrollment: 50
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: Given the apparent effect of 18 metabolic equivalent task-hours of activity/week in improving disease free survival in patients with treated stage 3 colon cancer and the survival benefit of exercise demonstrated in patients with stage II and III colorectal cancer, the primary objective is to evaluate compliance at 6 months with post-treatment recommendations for a minimum of 18 metabolic units of physical activity each week in patients who have completed therapy for stage 2 and stage 3 colorectal cancer.


Eligibility criteria: Inclusion Criteria:

1. Patients with histological confirmation of stage 2 or stage 3 colorectal cancer.
2. Ability to sign written informed consent.
3. WHO performance status of 2 or better.
4. No evidence of recurrent disease or death prior to second questionnaire.
5. Patients with declining physical activity within 90 days of second physical activity assessment will be excluded.

There are no exclusion criteria

Primary outcomes:
measure: Number of Participants Who Maintained an Exercise Regimen Average of 18 Metabolic Units (MET) Per Week or Greater
timeFrame: 6 months
Secondary outcomes:
measure: Disease-free Survival
timeFrame: after 6 months
measure: Recurrence-free Survival
timeFrame: after 6 months
measure: Overall Survival
timeFrame: after 6 months
Other outcomes:
Locations:
city: New York
country: United States
facility: Beth Israel Medical Center - Philipps Ambulatory Care Center
state: New York
city: New York
country: United States
facility: St. Luke's Roosevelt Hospital Center
state: New York
Study officials:
affiliation: Beth Israel Medical Center
name: Peter S Kozuch, MD
role: PRINCIPAL_INVESTIGATOR
References: